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Aims Lp(a) concentrations represent a major cardiovascular risk factor and are almost entirely controlled by one single
locus (LPA). However, many genetic factors in LPA governing the enormous variance of Lp(a) levels are still unknown.
Since up to 70% of the LPA coding sequence are located in a difficult to access hypervariable copy number variation
named KIV-2, we hypothesized that it may contain novel functional variants with pronounced effects on Lp(a) con-
centrations. We performed a large scale mutation analysis in the KIV-2 using an extreme phenotype approach.
...................................................................................................................................................................................................
Methods
and results
We compiled an discovery set of 123 samples showing discordance between LPA isoform phenotype and Lp(a)
concentrations and controls. Using ultra-deep sequencing, we identified a splice site variant (G4925A) in preferen-
tial association with the smaller LPA isoforms. Follow-up in a European general population (n= 2892) revealed an
exceptionally high carrier frequency of 22.1% in the general population. The variant explains 20.6% of the Lp(a)
variance in carriers of low molecular weight (LMW) apo(a) isoforms (P= 5.75e-38) and reduces Lp(a) concentra-
tions by 31.3 mg/dL. Accordingly the odds ratio for cardiovascular disease was reduced from 1.39 [95% confidence
interval (CI): 1.17–1.66, P= 1.89e-04] for wildtype LMW individuals to 1.19 [95%CI: 0.92; 1.56, P= 0.19] in LMW in-
dividuals who were additionally positive for G4925A. Functional studies point towards a reduction of splicing effi-
ciency by this novel variant.
...................................................................................................................................................................................................
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Conclusion A highly frequent but until now undetected variant in the LPA KIV-2 region is strongly associated with reduced
Lp(a) concentrations and reduced cardiovascular risk in LMW individuals.
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Translational perspective
A novel frequent variant in LPA specifically reduces Lp(a) in carriers
of low molecular weight (LMW) Lp(a) isoforms by 31.3 mg/dL. LMW
individuals commonly present an increased cardiovascular risk, but
positive carrier status for the variant abolishes this increased risk.
This has implications for clinical practice, patient stratification, and
treatment development. The selective reduction of Lp(a) in LMW
carriers and the resulting reduction in cardiovascular risk significantly
adds to previous studies indicating that Lp(a) lowering can be benefi-
cial. Moreover, our data indicate splicing modulation as a potential
novel mechanisms for Lp(a) lowering.
Introduction
Increased Lipoprotein(a) [Lp(a)] levels are present in 15–25% of the
population1 and confer an up to 2.5-fold increased cardiovascular dis-
ease (CVD) risk.2 Since Lp(a) levels are almost entirely controlled by
one single gene locus, the LPA gene, they represent one of the most
important genetically determined CVD risk factors. LPA encodes the
major structural protein of Lp(a),3 apolipoprotein(a) [apo(a)], and ac-
counts for >90% of Lp(a) variance.3
The LPA gene presents a peculiar gene structure, consisting of sev-
eral, highly homologous ‘kringle-domains’ (K) named KIV type 1 to 10
(KIV-1 to KIV-10). Of note, the KIV-2 domain is encoded by an hyper-
variable, 5.6 kb sized, coding copy number variation (CNV), that
encompasses two exons and is present in up to >40 copies per allele
causing a heterozygosity level in the population of >95%.3 It thus gen-
erates >40 protein size isoforms in the population. Individuals with at
least one low molecular weight allele (LMW; <14 KIV-2 repeats
which corresponds to <23 total KIV domains) present 5–10-fold
higher median Lp(a) plasma levels (50 mg/dL) than individuals with
high molecular weight isoforms (HMW; >_23 KIV; medians 5–
10 mg/dL).1 Therefore in heterozygous individuals, the shorter allele
determines assignment to LMW or HMW group and subsequently
the CVD risk.4 Of note, about 30% of the population miss one iso-
form in plasma despite being heterozygous on DNA level. The non-
secreted allele has been termed as ‘operational null allele’5 and in
Caucasians, HMW alleles are more likely to be non-expressed than
LMW alleles.
The number of KIV-2 repeats explains 40–70% of Lp(a) variance,3
but Lp(a) levels can vary by 200-fold even for alleles with the same
size.6,7 This suggests the existence of still unknown modifying genetic
variants. Genome-wide association studies indeed reported an im-
pressively large number of independent variants in LPA,8 but causal ef-
fects on Lp(a) levels have been shown only for few.9
Depending on the isoform size, up to 70% of the protein coding
sequence is derived from the KIV-2 CNV (see Supplementary
material online, Figures S1 and S2), but this region remained inaccess-
ible to large-scale mutation analysis until recently, since sensitivity of
Sanger sequencing was insufficient to detect one variant in up to 80
KIV-2 copies.10 This resembles observations in other genes with
multi-copy coding regions, where novel disease-causing variants
were found in similar ‘blind spots’ of the genome (e.g. MUC1,
MUC5AC, Kir2.6).11 The KIV-2 region thus represents a natural candi-
date region for new causal variants.
The ‘extreme-phenotype approach’12 is a powerful instrument to
enrich for functional mutations. The association between LMW
apo(a) isoforms and high Lp(a) concentrations is well established.3
We therefore reasoned that samples deviating clearly from this pat-
tern can be seen as ‘extreme phenotype’-samples and possibly carry
novel causal variants. We therefore compiled 123 samples for
sequencing. This set comprised samples showing discordance be-
tween Lp(a) isoform phenotypes and Lp(a) concentrations as well as
control samples. We sequenced the KIV-2 region in all samples, eval-
uated the effects of a promising KIV-2 splice site variant on Lp(a) con-
centrations in an European general population sample (n= 2892) and
determined its impact on CVD risk in a high risk population.
Subsequently, we confirmed its allelic localization using pulsed-field
gel electrophoresis and investigated its effects on in vitro splicing
assays and human liver mRNA.
Methods
Study design
Lp(a) levels and apo(a) isoforms were determined in three populations
(ntotal = 9581): SAPHIR (healthy working population, Austria, n= 1519),
GCKD (German Chronic Kidney Disease study, n= 5170) and KORA F4
(population-based study, Southern Germany, n= 2892). Details are given
in Supplementary material online, Methods and Table S1. A ‘discovery
sample’ of 123 individuals for sequencing was drawn from SAPHIR and
GCKD by belonging to either an extreme phenotype (low Lp(a) levels
despite LMW isoform or high Lp(a) values despite HMW isoform) or a
control group with expected Lp(a) levels (Table 1, see Supplementary
material online, Table S2 and Methods). A splice site variant and/or its cor-
responding proxy single nucleotide polymorphism (SNP) was followed
up in the entire KORA F4 and GCKD studies.
Lp(a) phenotyping and genotyping
All Lp(a) phenotyping was performed centrally at the Division of Genetic
Epidemiology, Innsbruck, Austria and evaluated by the same experienced
researcher, who was not involved in sequencing. Lp(a) concentration was
determined by ELISA and apo(a) isoform phenotyping was done by
Western blotting (see Supplementary material online, Methods). Peculiar
Western blot phenotypes were confirmed by repeated measurements.
For semi-quantitative determination of the relative contribution of both
alleles to the total Lp(a) amount in plasma in heterozygous individuals,
1824 S. Coassin et al.
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.the sum of both bands in Western Blot was assumed to be 100% and the
relative contribution of the smaller isoform was estimated.
KIV-2 batch amplification and next-
generation sequencing
The KIV-2 region was amplified using a ‘batch amplification’ approach,10,13
which leverages the homology of KIV-2 repeats to simultaneously amplify
all KIV-2 repeats as an amplicon mixture (Figure 1) and subjected to
ultra-deep next-generation sequencing (NGS). Like mitochondrial hetero-
plasmies, variants occurring only in a subset of repeats will be present only
in a corresponding subfraction of NGS reads. Data analysis was therefore
performed by aligning all reads to one single kringle repeat and low-level
variants were called using the highly specific14 mutation detection pipeline
‘mtDNA-Server’14 with slight adaptions (https://mtdna-server.uibk.ac.at/,
25 March 2017) (see Supplementary material online, Methods). The LPA
KIV-2 specific variant calling pipeline will be available at lpa-server.i-med.ac.
at, 25 March 2017 (manuscript in preparation). Two known splice site
....................................................................................................................................................................................................................
Table 1 Phenotypes of the discovery set
Phenotype Group n Lp(a) mg/dL
[median (IQR)]
Total KIV-2
repeats (qPCR)
[median (IQR)]
Short isoform
according
to Western blot
[median (IQR)]
G4925A
carrier, n (%)
HMW isoform, low Lp(a) Controls 28 3.1 (1.4–5.5) 47 (43–50) 33 (30–36) 4 (14.3)
LMW isoform, high Lp(a) Controls 15 55.7 (51.8–83.9) 32 (30–36) 15 (15–20) 1 (6.7)
High Lp(a) despite HMW isoform Extreme phenotype 33 66.0 (55.4–73.9) 43 (40–47) 30 (29–33) 1 (3.0)
Low Lp(a) despite LMW isoform Extreme phenotype 31 4.2 (3.0–6.9) 39 (36–44) 20 (19–22) 22 (71.0)
No isoforms detectable in
Western blot
Extreme phenotype 14 0.6 (0.3–0.9) 56 (47–59) n.a. 2 (14.3)
Othera Extreme phenotype 2 n.a. n.a. n.a. 2 (100)
Total 123
HMW, high molecular weight; IQR, interquartile range; LMW, low molecular weight; n.a., not applicable.
a1 multiple bands in the Western blot, 1 very faint 20 repeats isoform in the Western blot.
Figure 1 Concept of the batch sequencing approach. All KIV-2 repeats are amplified with the same primer pair by leveraging the high homology.
By aligning all repeats to one single copy, a variant occurring in only one repeat will be present only in a subset of amplicons. This resembles mito-
chondrial heteroplasmies or somatic mutations and can thus be detected using the same approaches.
A novel frequent variant in KIV-2 1825
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defects (rs41272114 and rs14343136815) were determined by Sanger
sequencing (see Supplementary material online, Tables S3 and S4). See
Supplementary material online, Methods for details, reference sequence se-
lection strategy and analysis of 1000Genomes and GenomeAustria
datasets.
G4925A genotyping by competitive allele-
specific TaqMan PCR
Given the technically demanding necessity to type a variant within up to
>70 KIV-2 copies, we used a custom-made commercial competitive
allele-specific TaqMan PCR (castPCR)16 assay (competitive allele-specific
TaqMan PCR; also known as ASB-PCR) (ThermoFisher Scientific). This al-
lele specific qPCR assay allows detection of somatic mutations down to
at least 0.1% level16 and thus provides sufficient sensitivity for determining
SNPs present in one of >70 KIV-2 repeats. For technical details, quality
figures from assay validation and quality control measures see
Supplementary material online, Methods.
Minigene assays and liver mRNA analyses
The G4925A variant is located at the donor splice site of the second KIV-2
exon, which is spliced to the first exon of the next KIV-2. Therefore a PCR
fragment spanning the short intron between two KIV-2 repeats as well as
the two boundary exons was subcloned into a pSPL317 minigene plasmid
by standard PCR subcloning techniques (see Supplementary material on-
line, Figures S3 and S4). In vitro splicing assays were performed in HepG2.
Details are given in Supplementary material online, Tables S5 and S6.
In order to study mRNA from G4925A carriers, we obtained liver biopsy
samples from a G4925A carrier and three G4925A-negative controls,
amplified the G4925A context from both mRNA and pre-mRNA and ana-
lysed these by NGS and castPCR. Additionally, the presence of exon skip-
ping was investigated (see Supplementary material online, Methods).
Pulsed field gel electrophoresis
Apo(a) isoforms in plasma and G4925A carrier status were determined
by Western blotting and castPCR in 40 fresh blood samples from
anonymous donors (Central Institute for Blood Transfusion, State
Hospital of Innsbruck, Austria). Seven out of 11 G4925A carriers pre-
sented both apo(a) alleles in plasma and 5 of these were subjected to
KIV-2 genotyping by pulsed field gel electrophoresis (PFGE) together
with six G4925A-negative controls. PFGE allows the determination of
the number of both KIV-2 present on genomic DNA,10 independently
from the occurrence of operational null alleles (see Supplementary ma-
terial online, Methods).
Statistical methods
Prevalence of G4925A in the discovery set phenotypic groups was com-
pared by Fisher exact test (two-sided) and relative contribution of the
smaller band in the Western blot to the total signal in Western blot was
compared by Wilcoxon test. The association of G4925A with Lp(a) was
tested in the entire KORA F4 study and in LMW/HMW subgroups by lin-
ear regression analysis. In KORA F4 and GCKD, regression analysis on
Lp(a) was also performed for the SNP rs75692336, which tags G4925A.
Finally, effects of the tagging SNP rs75692336, which serves as a proxy for
G4925A, on CVD prevalence in the GCKD study were tested by a logis-
tic regression. For details on statistical methods and the tagging SNP ap-
proach see the Supplementary material online, Methods.
Results
Mutation analysis
We ultra-deep sequenced the KIV-2 repeat in 123 individuals [drawn
from the 2 populations (SAPHIR and GCKD, ntotal = 6689)] either
showing discordance between Lp(a) isoform phenotype and Lp(a)
concentrations: (i) low Lp(a) despite LMW isoform, (ii) high Lp(a)
despite HMW isoform, (iii) no detectable isoform in blood or to a
control group, (iv) LMW with high Lp(a) concentrations, and (v)
HMW with expected Lp(a) concentrations (Table 1, see
Supplementary material online, Table S2).
The two known functional SNPs rs41272114 and rs14343136815
did not explain the observed extreme phenotypes (see Supplementary
material online, Table S7). Ultra-deep NGS (average depth: 24 418)
and dedicated low-level mutation detection of ‘batch amplification’13
products (Figure 1) revealed, however, a novel variant in the exonic
donor splice site of the second KIV-2 exon, which was strongly over-
represented in the phenotype ‘low Lp(a) levels despite LMW isoform’
(71% carriers compared to 11% in all other groups combined,
PFisher = 4.47e-10; Table 1). Since unique position annotation is not pos-
sible, we use our working name G4925A throughout the manuscript
[Human Genome Variation Society (HGVS) annotation provided in
Supplementary material online, Methods]. By dividing the NGS muta-
tion level by the total number of KIV-2 repeats estimated by KIV-2
qPCR, we estimate that the variant occurs mostly in only one or two
of all KIV-2 repeats present in an individual (see Supplementary mater-
ial online, Figure S5). Despite its seemingly high frequency and its prom-
ising location, the variant has thus likely escaped detection in earlier
studies10,13 due to insufficient sensitivity of Sanger sequencing.
Next-generation sequencing validation
and population data
We analysed three public datasets [1000G Exome samples with
>1000 coverage at the variant position (n= 1589, 26 populations),
1000G high-coverage whole-genome samples (n= 30),
GenomeAustria whole-genome samples (n= 8)] to exclude technical
artefacts in our sequencing procedure and investigate the frequency
of G4925A in different populations on the other hand (see
Supplementary material online, Methods and Tables S4–S7). Despite
different sequencing technologies, G4925A was observed in all three
control datasets. Largely varying frequencies were observed in the
1000Genomes populations (Figure 2, see Supplementary material on-
line, Tables S8–S11).
Association study in the general
population
To assess the impact of G4925A in the general population, we deter-
mined the G4925A carrier status in the population-based study
KORA F4 (n= 2892; Southern Germany) using highly sensitive
castPCR (validation results shown in Supplementary material online,
Table S12). The frequency of G4925A carriers in KORA F4 was
22.1% and carriers preferentially presented a smaller apo(a) isoform
with 19-25 KIV (Figure 3A). 56.4% of all carriers presented a smaller
apo(a) isoform with 23 or 24 KIV. These isoforms represent a thresh-
old at which the median Lp(a) concentrations suddenly decrease from
45–50 mg/dL in carriers of isoforms with <_22 KIV to 10 mg/dL in
1826 S. Coassin et al.
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carriers of >_23 KIV isoforms1 (see Supplementary material online,
Figure S6). This sudden decrease is smoothened when accounting for
G4925A carrier status (Supplementary Figure S6), thus indicating that
G4925A might substantially account for this observation.
G4925A carrier status was highly significantly associated with
inverse-normal transformed Lp(a) concentrations in the clinically
relevant LMW group (encompassing 24.6% of the population): posi-
tive G4925A carrier status was associated with Lp(a) reduction by
31.3 mg/dL, explaining 20.6% of Lp(a) variance (P= 5.75e-38) (Figure
3B). After adjustment for KIV number, the association became highly
significant also in the total population (P= 1.05e-55) and in the HMW
group (KORA F4 HMW: P= 1.69e-10). In contrast, the association in
the LMW group was virtually unaffected by isoform adjustment
(P= 3.0e-36). Full results are reported in Table 2.
Association with cardiovascular disease
in the GCKD study group
We reasoned that the strong Lp(a) reduction in LMW individuals
with positive G4925A carrier status may alleviate LMW-mediated
CVD risk. A direct evaluation of the effect of G4925A on CVD is
hampered by the fact that variants in KIV-2 are not contained in the
imputed whole-genome SNP datasets commonly available in large,
genetic-epidemiological studies on CVDs. By combining 1000G-
imputed SNP data and G4925A data in KORA F4 (see
Supplementary material online, Methods), we identified rs75692336
as proxy for G4925A (r2 = 0.82, D’ = 0.99) (see Supplementary ma-
terial online, Table S13). The minor allele of rs75692336 was
associated with a similar, but slightly smaller Lp(a) reduction than
G4925A (see Supplementary material online, Table S14).
This proxy SNP was then used to assess the effect of G4925A on
CVD in the high risk GCKD population. rs75692336 was associated
with lower odds ratio (OR) for CVD following a dominant model
(see the Supplementary material online, Methods for the rationale of
the model selection). When comparing LMW individuals of GCKD
to HMW individuals of GCKD, the LMW individuals present an
increased risk for CVD, as would be expected4 (OR = 1.34,
P= 6.29e-05) (Table 3). However, when the population is stratified
according to G4925A carrier status, this risk elevation in LMW indi-
viduals carrying also a minor allele of rs75692336 is no longer signifi-
cant (OR = 1.19, P= 0.19) (Table 3). Conversely, in LMW individuals
not carrying G4925A the CVD risk was even slightly higher than in
the whole population (OR = 1.39, P= 1.89e-04). The results from the
extended adjustment model remained very consistent to the un-
adjusted model (Table 3).
Molecular analysis of G4925A
localization
Figure 3A suggests that the G4925A is located on smaller LPA alleles
and Figure 4 shows that in KORA F4 samples presenting both iso-
forms in plasma the contribution of the small allele to the total
Western blot signal was significantly lower in G4925A carriers than
in wild-type samples [PWilcoxon = 0.0041 (all samples) and
PWilcoxon = 2.42e-09 (LMW samples only); Figure 4]. This indicates a
reduced protein amount originating from this allele. To investigate
Figure 2 G4925A carrier frequency in the 1000 Genomes populations. Only exome data with >1000 coverage from unrelated samples were
used (n= 1589). The total number of individuals passing the coverage requirements and the G4925A overall frequency (F) in each super population
is reported on the x-axis. Details and population code are given in Supplementary material online, Tables S8 and S9. Admixed African populations
(ACB and ASW) were excluded from this figure, but are reported in Supplementary material online, Table S8. In Chinese Dai in Xishuangbanna
(CDX), only five individuals passed the coverage requirements.
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D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/38/23/1823/3748449 by guest on 22 O
ctober 2019
Figure 3 Distribution and effects of G4925A. (A) Carrier frequency in the single isoform groups (based on the smaller isoform). The values report the
percentage of wild type (wt), respectively G4925A carriers that present the mentioned isoform. The variant clusters in isoforms19–25, peaking at 23
and 24 (32.7% and 23.7% of all carriers). (B) Median Lp(a) concentrations depending on isoform and carrier status (solid line). The variant is associated
with lower Lp(a) concentrations throughout the whole isoforms range with the most pronounced effect in LMW carriers (defined <_22 KIV repeats).
Dotted lines: 1st and 3rd quartile. Isoform was binned to encompass >_10 carrier per group (except for isoforms >34, n= 9). WB: Western blot.
....................................................................................................................................................................................................................
Table 2 Results of association study of G4925A on Lp(a) concentrations
Group binverse norm boriginal P-value Variance explained (%)
a
Unadjusted model
KORA F4 all (n= 2892) -0.122 -8.1 0.006 0.2
KORA F4 LMW only (n= 716) -0.891 -31.3 5.57e-38 20.6
KORA F4 HMW only (n= 2176) 0.054 -2.5 0.231 0.02
Adjusted model (isoform-adjusted)
KORA F4 all (n= 2864) -0.618 -21.3 1.05e-55 6.1
KORA F4 LMW only (n= 715) -0.868 -30.6 3.0e-36 19.3
KORA F4 HMW only (n= 2149) -0.310 -10.0 1.69e-10 1.6
P-value, binverse norm, and explained variance (R
2) are based on linear regression from G4925A carrier status on inverse normal-transformed Lp(a) concentrations. Additional
effect estimates were obtained from linear regression on the original Lp(a) scale in mg/dL (boriginal).
aFor the adjusted model, this represents the variance explained by G4925A additionally to apo(a) isoforms.
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whether the variant is truly located on the short allele, we selected
11 healthy volunteers (five G4925A carriers), who presented both
protein isoforms in plasma, separated genomic LPA alleles by PFGE,
isolated the 2 alleles from the gel as previously described10 and tested
the separated alleles by castPCR. In all carriers, the G4925A variant
was indeed localized of on the Lp(a) level-determining short LPA al-
lele. This provides an important prerequisite for a true functional im-
pact of G4925A on Lp(a) levels.
In vitro analysis of functional effects of G4925A
Although occurring at a splice site, G4925A was not associated
with null alleles (see Supplementary material online, Figure S7).
Since LPA is exclusively liver-expressed3 and human mRNA is
therefore utmost difficult to obtain, we used comprehensive
pSPL317 minigenes (see Supplementary material online, Figure S3;
assay concept explained in Supplementary material online, Figure
S8) to assess splicing patterns in HepG2 cells. In our analyses, the
minor allele (A) abolished splice site recognition in vitro and acti-
vated a cryptic intronic splice site leading to retention of the first
87 intronic bases and resulting in inclusion of a premature stop
codon in vitro (see Supplementary material online, Figures S4 and
S9). The comparison of PFGE and Western blot data from
G4925A carriers and controls (see Supplementary material online,
Table S15) indicated that in vivo the reduced splicing efficiency of
the minor allele does not result in a complete protein truncation,
but rather in a clear reduction of the abundance of the (variant-car-
rying) small allele (Figure 4). To investigate this observation, we ob-
tained mRNA from liver biopsies of a G4925A carrier and three
controls and analysed a RT-PCR product, which bridged the exon–
intron boundary at G4925A (see Supplementary material online,
Figure S10) by deep sequencing. The occurrence of the A-allele in
the mature mRNA was below detection limit and only the G allele
was detected, while a castPCR on an amplicon amplifying the
G4925A context sequence from pre-mRNA instead of mature
mRNA was still positive for the A allele, suggesting loss of the
variant A allele during mRNA maturation (discussed below). No
exon skipping was observed (see Supplementary material online,
Figure S11).
Discussion
The LPA gene represents a major CVD risk locus and the measure-
ment of Lp(a) is especially recommended in people with high CVD
risk or a strong family history of premature atherothrombotic dis-
ease.18 Several independent association signals for Lp(a) have been
described in LPA region,8 but a consistent portion was inaccessible to
mutation screening until recently. Accordingly, factors governing the
variance of the Lp(a) besides the KIV-2 repeat are still largely
unknown.
............................................................. .............................................. ..............................................
....................................................................................................................................................................................................................
Table 3 Association of LMW apo(a) isoforms with cardiovascular disease risk in the GCKD study (compared to high
molecular weight isoform), for all participants and also stratified by the carrier status for at least one rare allele of
rs75692336 (proxy to G4925A)
Number (%) of CVD events in Unadjusted model Adjusted modela
Group LMW group HMW group OR [95% CI]
(LMW vs. HMW
carriers)
P-value OR [95% CI]
(LMW vs. HMW
carriers)
P-value
All (n= 4883) 368 of 1208 (30.5%) 905 of 3675 (24.6%) 1.34 [1.16–1.54] 6.29e-05 1.35 [1.16;1.58] 1.49e-04
rs75692336 carrier
(CA/AA) (n= 1151)
127 of 425 (29.9%) 191 of 726 (26.3%) 1.19 [0.92–1.56] 0.19 1.21 [0.90;1.63] 0.20
rs75692336 non-carrier
(CC) (n= 3732)
241 of 783 (30.8%) 714 of 2949 (24.2%) 1.39 [1.17–1.66] 1.89e-04 1.40 [1.16;1.70] 4.41e-04
HMW, high molecular weight; LMW, low molecular weight; CVD, cardiovascular disease; CI, confidence interval; OR, odds ratio.
aAdjusted for age, gender, type 2 diabetes, LDL-cholesterol corrected for lipid-lowering medications and Lp(a), log(triglycerides), eGFR and log(UACR).
Figure 4 Relative contribution of the smaller apo(a). Western
blot band to the total Western blot signal. Assuming the summed
Western blot signal of both alleles being 100%, we estimated the
contribution of the smaller allele to the total (see Methods). The
contribution of the smaller allele to the circulating Lp(a) was signifi-
cantly lower in carriers of G4925A (Wilcoxon test).
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.In the work at hand, we identified a novel variant that overrides
the major effect of LMW isoforms on Lp(a) concentrations and is
associated with a pronounced Lp(a) reduction. It exerts its largest ef-
fect in the LMW group (Figure 3), which is commonly associated with
increased Lp(a) levels and CVD risk.4 Conversely, in the HMW group
and in the total population its effect was initially masked by its associ-
ation with smaller isoforms at 23–25 KIV (explained detail in
Supplementary material online, Figure S12). This observation reminds
the regulatory variant rs1853021, whose effect is masked by its asso-
ciation with HMW isoforms,19 and exemplifies how failure to ac-
count for apo(a) isoforms in association studies can mask the effect
of high-impact variants. It suggests a complex interplay of KIV-2 num-
ber and SNPs in determining the Lp(a) levels. G4925A seems instru-
mental both in the large concentration range observed especially in
LMW isoforms (Figure 3) as well as in the sudden Lp(a) decrease at
23-24 KIV (see Supplementary material online, Figure S6).
Using a proxy SNP present in common imputed data sets we fi-
nally show that the G4925A carrier status modifies the genetic CVD
risk of LMW individuals (which would otherwise be at high genetic
CVD risk). This confirms recent studies on other, rarer variants asso-
ciated with low Lp(a),15,20 which reported similar CVD risk reduc-
tions. Given the high frequency in the population, we anticipate, that
inclusion of G4925A status in studies assessing the impact of Lp(a)
isoforms may increase discrimination.
The mechanism behind G4925A-mediated Lp(a) lowering is intri-
guing and warrants further research. We show that G4925A affects
splice site recognition in vitro. By combining Western blot and
castPCR on PFGE-separated alleles, we also show that G4925A is
indeed located on the Lp(a) level-determining small allele and is asso-
ciated with a reduced amount of protein originating from this allele
(Figure 4). The detection of a guanosine instead of the expected ad-
enosine in the mature liver mRNA of a mutation carrier would be
consistent with an ‘A-to-I RNA editing’21 mechanism, since the ex-
pected adenosine was still detected in amplicons on pre-mRNA from
of the same sample.
A-to-I RNA editing happens during maturation of pre-mRNA to
mRNA where ADAR enzymes desaminate adenosines to inosines
that are then interpreted by the cell (and PCR) as guanosines.21
Indeed, in silico mRNA structure modelling predicts extended
double-stranded RNA structures at G4925A (see Supplementary
material online, Figure S13), which represent canonical RNA editing
recognition motifs.21 In addition, both the nucleotide context of
G4925A (5’-A-[G4925A]-G-3’)22 and inefficient splicing23 have been
shown to strongly promote editing. We hypothesize that G4925A
reduces splice site recognition, as shown by our in vitro assays, which
in turn prolongs nuclear retention and promotes so editing of the
A-allele to the wild-type guanosine, explaining so why only guano-
sines are detected in RT-PCR NGS on mature mRNA. Not much is
known about editing of protein-coding genes, but hyperedited Alu
repeat mRNA has been shown to undergo mRNA decay.21 Several
lines of evidence therefore argue for a combination of reduced splic-
ing efficiency and possibly RNA editing-related processes as mechan-
istic basis for the observed association. These mechanisms might
finally lead to the observed reduced contribution of the short allele
to the total apo(a) protein level in plasma. Indeed, Lp(a) levels are
known to be mainly determined by synthesis rate9 and are modifiable
Figure 5 Summarizing illustration of the key messages of this article.
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by LPA expression modulation (reviewed in3). Future, in-depth stud-
ies in large collections of native human liver samples will be needed
to test this working hypothesis.
Our study has strengths and limitations. We describe a novel,
highly frequent variant in the highly repetitive KIV-2 with a pro-
nounced effect on Lp(a) concentrations and describe methods to
type this variant. The variant was confirmed in 1000G data and in a de
novo typed, large Caucasian general population-based sample. The
widely varying levels between the different 1000G populations argue
against ‘phantom mutation’ at a sequencing error hot spot. We also
show that the variant reduces CVD risk in individuals at otherwise
high genetic CVD risk. The use of a proxy SNP presents for CVD risk
estimation can be seen as a limitation but is supported by the very
similar effect size of the proxy on Lp(a) and allows the replication and
extension of our findings by others (provided LPA isoform data for
adjustment are available). Additional replication in possibly even
larger studies on CVD with apo(a) isoform data available will be cru-
cial to establish the role of our findings. Albeit G4925A location is
likely to be functional and we provide first mechanistic insights in the
Lp(a) lowering mechanism, we clearly cannot completely exclude
that a variant in linkage disequilibrium is the real causal one.
In conclusion, our investigation summarized in Figure 5 adds to pre-
vious works showing the utility of sequencing under genome-wide
association study (GWAS) peaks. We identified a highly frequent
splice site variant, which markedly reduces CVD risk in LMW carriers
and is instrumental in the strikingly large range of Lp(a) levels
observed in LMW carriers.6,7 Much emphasis has been put on the
deleterious consequences of high Lp(a) (reviewed in24), but Lp(a)
function remains elusive. The investigation of variants causing low
Lp(a) might therefore provide novel perspectives (as recently
shown15,25) and our observations on G4925A-mediated Lp(a) reduc-
tion highlights splicing efficiency modulation by antisense oligos or
transsplicing26 as a potential novel Lp(a) lowering approach .
Supplementary material
Supplementary material is available at European Heart Journal online.
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